Find what matters to you

Rho has once again been chosen as a winner of Triangle Business Journal’s 2023 Best Places to Work Awards. This is the 11th year Rho has been recognized for the Triangle Business Journal’s award “a prestigious award that honors companies for creating policies and a work environment that employees value.”

One of the most rewarding aspects of this recognition is that it is driven by employee surveys, which are then tabulated and ranked by Quantum Workplace. Rho is honored and proud to receive high marks in areas such as team effectiveness, trust with co-workers, manager effectiveness and work engagements from our employees.

Rho received Clinical Leader and Life Science Leader’s 2023 CRO Leadership award, marking a long history as an award recipient. Forty-six CROs were evaluated on more that 20 different performance metrics. Respondents evaluated companies with which they have worked on an outsourced project within the past 18 months. This level of qualification ensures that survey responses are based on actual involvement with CROs and clear experiential data.

Rho was recognized for Exceeding Customer Expectations in Compatibility and Quality and received 4 Individual Attribute Awards in Data Quality, Technology for Real Time Access to Data, Therapeutic Expertise and Operational Excellence.

Biometrics services (data management, biostatistics, data standards, and statistical programming) can be outsourced together as a unit or individually with different CRO partners. While splitting services up is perfectly acceptable, there are potential benefits that could be realized by having one contract research organization (CRO) support both the data management and biostatistical/programming components for your clinical trial project or program.

Nine out of 10 clinical trials for new drugs fail; Oncology drugs have a 3.4 percent probability of succeeding. Still, cancer drugs can and are being commercialized. From 2003 to 2020, 124 oncology therapies were approved by FDA. What makes this possible? Knowing the key factors to consider at each juncture

Since the introduction of the original 3+3 method, the available design options for dose escalation in early phase studies have expanded beyond traditional algorithm-based designs to include model-based designs.

Oncology dose-escalation trials are a distinct entity, with nuances and considerations which set them apart from other therapeutic areas. From varying trial designs to the patients who participate, dose-finding clinical trials in oncology are a clinical research paradigm. Understanding strategies to facilitate success is key to study planning and execution, from feasibility to site selection through enrollment and treatment.